Semaglutide improves cardiometabolic risk factors in adults with overweight or obesity: STEP 1 and 4 exploratory analyses
Diabetes, Obesity and Metabolism · 2023-02 · 25 (2) · 468-478
DOI: 10.1111/dom.14890 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 28.10.2022. Verfasst von Mikhail N Kosiborod und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Disease, Saint Luke's Mid America Heart Institute and University of Missouri-Kansas City School of Medicine, Kansas City…. Hauptthemen laut MEDLINE: Insulins, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 129-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIDDK NIH HHS, Novo Nordisk.
Abstract (Originalsprache)
Aims Evaluate the effects of once‐weekly subcutaneous semaglutide 2.4 mg on cardiometabolic risk factors in people with overweight/obesity without diabetes in the STEP 1 and 4 trials. Materials and Methods STEP 1 and 4 were phase III, 68‐week, placebo‐controlled trials of once‐weekly semaglutide 2.4 mg combined with lifestyle intervention; STEP 4 had a 20‐week semaglutide run‐in and 48‐week randomized withdrawal period. Participants had a body mass index ≥30 kg/m 2 or ≥27 kg/m 2 with one or more weight‐related comorbidity, without diabetes. Pre‐specified endpoints were changes in waist circumference, systolic/diastolic blood pressure (SBP/DBP), lipids, fasting plasma glucose (FPG), fasting serum insulin and antihypertensive/lipid‐lowering medication use. Post‐hoc assessments included non‐high‐density lipoprotein (HDL) cholesterol, homeostatic model assessment of insulin resistance (HOMA‐IR; STEP 1 only), atherosclerotic cardiovascular disease (ASCVD) risk (American College of Cardiology/American Heart Association algorithm; STEP 1 only) and cardiometabolic risk factors by weight loss achieved (
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiovascular Disease, Saint Luke's Mid America Heart Institute and University of Missouri-Kansas City School of Medicine, Kansas City, Missouri, USA.
- Novo Nordisk A/S, Søborg, Denmark.
- Diabetes Research Centre, University of Leicester, Leicester, UK.
- NIHR Leicester Biomedical Research Centre, Leicester, UK.
- Institute of Cardiovascular Science, University College London, London, UK.
- Department of Nutrition Sciences, University of Alabama at Birmingham, Birmingham, Alabama, USA.
ORCID-Profile: Mikhail N Kosiborod, Melanie Davies
Förderung
- NIDDK NIH HHS
- Novo Nordisk
Zitieren
APA
Kosiborod, M. N., Bhatta, M., Davies, M., Deanfield, J. E., Garvey, W. T., Khalid, U., Kushner, R., Rubino, D. M., Zeuthen, N., & Verma, S. (2023). Semaglutide improves cardiometabolic risk factors in adults with overweight or obesity: STEP 1 and 4 exploratory analyses. Diabetes, Obesity and Metabolism, 25(2), 468-478. https://doi.org/10.1111/dom.14890
Vancouver
Kosiborod MN, Bhatta M, Davies M, Deanfield JE, Garvey WT, Khalid U, et al. Semaglutide improves cardiometabolic risk factors in adults with overweight or obesity: STEP 1 and 4 exploratory analyses. Diabetes, Obesity and Metabolism. 2023;25(2):468-478. doi:10.1111/dom.14890
BibTeX
@article{Kosiborod2023,
author = {Kosiborod, Mikhail N and Bhatta, Meena and Davies, Melanie and Deanfield, John E and Garvey, W Timothy and Khalid, Usman and Kushner, Robert and Rubino, Domenica M and Zeuthen, Niels and Verma, Subodh},
title = {Semaglutide improves cardiometabolic risk factors in adults with overweight or obesity: STEP 1 and 4 exploratory analyses},
journal = {Diabetes, Obesity and Metabolism},
year = {2023},
volume = {25},
number = {2},
pages = {468--478},
doi = {10.1111/dom.14890}
}
EUVIMED